Zidovudine 300mg / Lamivudine 150mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Zidovudine + Lamivudine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Zidovudine + Lamivudine on the MHRA register
Combivir 150mg/300mg tablets
Zidovudine 300mg / Lamivudine 150mg tablets
Zidovudine 300mg / Lamivudine 150mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 22 · 1995–2025
Showing the 50 most relevant studies, sorted by most relevant.
Gilles Pialoux, François Raffi, Françoise Brun‐Vézinet, et al.
New England Journal of Medicine, 1998
- Remission Induction
- RNA, Viral
- Zidovudine
The Lancet, 2002
- Breast Feeding
- Infant Mortality
- South Africa
Dhayendre Moodley, Jagidesa Moodley, Hoosen Coovadia, et al.
The Journal of Infectious Diseases, 2003
- HIV-1
- Labor, Obstetric
- Pregnancy Complications, Infectious
Schlomo Staszewski
JAMA, 2001
- Abacavir
- Drug Resistance, Microbial
- Genotype
CAESAR Coordinating Committee, [Unknown], Study group members AMC, :, Kroon, E.D.M.B., et al.
The Lancet, 1997
- Acetamides
- Acetophenones
- Acquired Immunodeficiency Syndrome
Daniel R. Kuritzkes, Joseph Quinn, Sharon L. Benoit, et al.
AIDS, 1996
- Drug Resistance
- Genes, Viral
- Mutation
Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, et al.
The Lancet HIV, 2022
- HIV-1
- HIV Infections
- Tenofovir
Cowdell I, Beck K, Hey M, et al.
2025
- Pregnancy Complications, Infectious
- HIV Infections
- Reverse Transcriptase Inhibitors
BackgroundThe WHO recommends antiretroviral therapy (ART) containing two nucleoside reverse transcriptase inhibitors (NRTIs) as backbone. WHO recommends tenofovir disoproxil fumarate combined with lamivudine or emtricitabine as first line in pregnancy, and zidovudine, abacavir or tenofovir alafenamide, combined with lamivudine or emtricitabine, as alternatives.ObjectivesThis study aims to evaluate the risk of adverse perinatal outcomes in pregnant women living with HIV (WLHIV) receiving different NRTIs.MethodsData sources included Medline, CINAHL, Global Health, and Embase.Study eligibility criteriaCohort studies.ParticipantsPregnant WLHIV.InterventionsART regimens containing different NRTI drugs.Assessment of risk of biasNewcastle-Ottawa Scale and Grading of Recommendations Assessment, Development and Evaluation.Methods of data synthesisRandom-effects meta-analysis.ResultsIn total, 22 cohort studies including 124,478 pregnant WLHIV met the eligibility criteria. ART containing tenofovir disoproxil fumarate was associated with lower risk of preterm birth (risk ratio, 0.89; 95% CI, 0.81-0.97), very preterm birth (0.58; 0.40-0.86), small for gestational age (0.76; 0.59-0.98), very small for gestational age (0.60; 0.48-0.73), stillbirth (0.49; 0.31-0.78), and neonatal death (0.61; 0.40-0.93), compared with ART not containing tenofovir disoproxil fumarate. ART containing zidovudine was associated with an increased risk of very preterm birth (1.59; 1.01-2.49), small for gestational age (1.33; 1.03-1.70), very small for gestational age (1.63; 1.25-2.13), stillbirth (2.23; 1.10-4.55), and neonatal death (1.65; 1.08-2.52), compared with ART not containing zidovudine. For ART regimens also containing either lamivudine or emtricitabine, zidovudine was associated with an increased risk of very preterm birth (1.62; 1.04-2.52), small for gestational age (1.52; 1.28-1.82), very small for gestational age (1.68; 1.36-2.06), stillbirth (2.19; 1.03-4.67), and neonatal death (1.65; 1.08-2.52), compared with ART containing tenofovir disoproxil fumarate. Abacavir was not associated with adverse perinatal outcomes. Tenofovir alafenamide was not associated with low birthweight compared with tenofovir disoproxil fumarate.ConclusionsTenofovir disoproxil fumarate is associated with a lower risk of adverse perinatal outcomes, whereas zidovudine is associated with an increased risk of perinatal outcomes. Abacavir is not associated with adverse perinatal outcomes. Our findings support current WHO guidelines.
Abstract licence: CC BY
Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.
Antiviral Therapy, 2002
- HIV-1
- Argentina
- RNA, Viral
Milos Opravil, Bernard Hirschel, Adriano Lazzarin, et al.
The Journal of Infectious Diseases, 2002
- HIV-1
- Abacavir
- Acquired Immunodeficiency Syndrome
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.